Figure 7.
A graphical diagram of PHA-665752’s antigrowth, proapoptotic, and antiangiogenic mechanisms in HSC-3 cells. PHA may directly inhibit its target c-Met and its downstream effector pathways. PHA may also indirectly regulate additional factors, including Mcl-1, HIF-1α, Src, PKB, and mTOR. These alterations will contribute to the drug’s antisurvival, proapoptotic, and antiangiogenic effects on HSC-3 cells. The red arrows mean downregulation.